FIELD: medicine, nephrourology. SUBSTANCE: method deals with treating uremia. For this purpose one should introduce gel form of finely divided chitosan either per oral or through a probe per 4 ml/kg body weight in every 3 h. The method leads to efficient detoxication at uremia of different genesis, in incurable patients in case of prolongation of predialysis terms when active methods of therapy are contraindicated, as well. EFFECT: higher efficiency of therapy. 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ENTEROSORBENT FOR TREATING RENAL INSUFFICIENCY | 1994 |
|
RU2097046C1 |
| METHOD OF PANCREATITIS DESTRUCTIVE FORM TREATMENT | 2001 |
|
RU2196587C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH STAGE V CHRONIC KIDNEY DISEASE AT DIALYSIS STAGE | 2020 |
|
RU2753127C1 |
| METHOD FOR ESTABLISHING UREMIC GENESIS OF POLYNEUROPATHY | 2006 |
|
RU2314527C1 |
| METHOD FOR REMOVING FUNCTIONAL DUODENOSTASIS IN CASE OF PANCREONECROSIS | 2003 |
|
RU2240802C1 |
| METHOD FOR DETERMINING UREMIC ENCEPHALOPATHY DEVELOPMENT DEGREE IN PATIENTS SUFFERING FROM CHRONIC RENAL INSUFFICIENCY | 2004 |
|
RU2272562C1 |
| TREATING ENDOTOXICOSIS IN PATIENTS WITH DESTRUCTIVE PANCREATITIS | 1999 |
|
RU2199326C2 |
| ENTEROSORPTION METHOD | 1997 |
|
RU2122868C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE C3-C5 AT DIALYSIS STAGE, EXCLUDING PYELONEPHRITIS, UROLITHIASIS | 2017 |
|
RU2646467C1 |
| AGENT FOR LOW-METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY | 2012 |
|
RU2485957C1 |
